Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management

Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates to first-line treatment, most patients will relapse shortly after and the outc...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Critical reviews in oncology/hematology 2022-06, Vol.174, p.103683-103683, Article 103683
Hauptverfasser:	Bellmunt, Joaquim, Valderrama, Begoña P., Puente, Javier, Grande, Enrique, Bolós, M. Victoria, Lainez, Nuria, Vázquez, Sergio, Maroto, Pablo, Climent, Miguel Ángel, Garcia del Muro, Xavier, Arranz, José Ángel, Durán, Ignacio
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibody drug-conjugate (ADC) Avelumab Bladder cancer Checkpoint inhibitors (CPIs) Platinum-based chemotherapy Switch maintenance Urothelial carcinoma (UC)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!